** Shares of LBT Innovations rise as much as 73.3% to A$0.026, their highest since April 5
** Stock posts its biggest intraday pct gain since March 13
** Medical technology firm says it has signed agreement to sell five APAS Independence instruments to AstraZeneca with total contract value between $2.2 mln and $2.7 mln
** APAS Independence is an in vitro diagnostic instrument for the automated imaging, analysis and interpretation of agar culture plates
** About 9.9 mln LBT shares change hands, compared with the 30-day average volume of 1.5 mln
** Stock had risen 36.4% this year, as of last close
(Reporting by Sneha Kumar in Bengaluru)
((Sneha.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。